- This event has passed.
Building on biotechnology: From vaccines to economic growth for Europe
EuropaBio National Associations Council
Summit 2021 – Portugal
10 May 2021 @ 3:00 pm – 6:00 pm CEST
EuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. The NAC represents biotechnology priorities across Europe’s Member and partner countries, working together to build long term economic and societal benefit from biotechnology across sectors.
In 2021, the NAC is proud to host its first Summit focussed on priorities for commercial biotechnology development, delivering the Industrial Strategy within national and European ecosystems.
The NAC summit on May 10 will address how we learn from the COVID-19 response, to enable full societal and economic benefit from biotechnology in the future across sectors. Rapid technology development pathways, including partnering, investment and approvals, created in response to the pandemic have created new, faster routes to market. Although this was a unique scale and speed for vaccine development, it shows that biotech can perform quickly and strongly to address unmet issues in healthcare and sustainable development, creating a solution and also supporting economic recovery across Europe.
The EuropaBio NAC Summit is held during the Portuguese Presidency of the Council of EU and organized in collaboration with P-BIO. The outcomes from the Summit will include a EuropaBio NAC Position on building economic pathways from biotech post-Covid with the role of aligned and ambitious national policies and actions.
Agenda
15:00: Welcome – Claire Skentelbery, Director General, EuropaBio
15:05: Opening remarks – Manuel Heitor, Minister of Science, Technology and Higher Education, Portugal
15:15: A European ambition in a competitive global landscape.
Where biotech and economic ambitions sit within European and global strategies – Claire Skentelbery, Director General, EuropaBio
15:30: Session 1 – A new biotechnology ecosystem in Europe
Companies active in the current response to Covid-19 share how they have built vital collaborations across the biotech-pharma spectrum to deliver breakthrough vaccine technologies to patients at unprecedented speed, plus how they envision future potential.
15:30: Economic development driven by Biotech – the Portugal perspective: David Malta, Founding CEO, LiMM Therapeutics
15:45: Developing bio-manufacturing partnerships – Elke Grooten, Head of EU Relations, Novartis
16:00: Pharma-SME collaboration: from innovation to patient, a global journey – Sinan Atlig, Regional President IDM, Vaccines Pfizer
16:15: Break
16:30: Session 2 – Looking to the future – speed and strength from biotech
SMEs driving next generation biotechnology present the pathway and challenges to success and highlight what Europe needs to achieve. EuropaBio National Associations will then discuss the critical framework needed to build further from national and European ecosystem advances from Covid, accelerating biotech contribution to Europe’s economic development.
SME drivers
16:30: The future of vaccines – Bruno Santos, Co-Founder and CEO, IMMUNETHEP
16:40: Reaching all patients for immunity – Kim Kjøller, CEO, UNION Therapeutics
Building European strengths
16:50: Discussion Panel – Associations from across Europe plus audience contributions
Moderator: Claire Skentelbery
Panellists:
– Agne Vaitkeviciene, Executive Director, Lithuanian Biotechnology Association
– Chloe Evans, Market Research Manager & International Relations, France Biotech
– Simão Soares, President, P-BIO
– Hanne Mette Dyrlie Kristensen, CEO, The Life Science Cluster (Norway)
18:00: Summary and Close
VIRTUAL EVENT
Who should attend?
The EuropaBio NAC Summit is open and free of charge. You should attend if you are active within the development of biotechnology ecosystems at national or European levels, either as a technology stakeholder (academic or industrial) or a facilitator of technology maturation to market and patients (associations, tech transfer, investors, policy makers…). The event will have a strong discussion element and all participants can be actively involved. The event will also develop preparatory statements for delegate feedback plus post-event discussion on the planned NAC Position.
Download below the speakers’ presentations: